A vial’s label can name a compound. It cannot prove what is inside.

That distinction was stark in a 14 September 2026 safety advisory from Australia’s Therapeutic Goods Administration (TGA). After a consumer was hospitalised with uncontrollable vomiting and an oesophageal tear, testing of an unmarked vial sold as retatrutide found no retatrutide. The TGA reported that it contained undeclared semaglutide, at approximately eight times the level detected in semaglutide products assessed by the regulator.

The central quality failure was substitution: the product’s identity did not match the label. This is different from contamination or under-dosing. It also shows why a high purity percentage means little if the main compound has not first been shown to be the compound declared.

What the case tells us, and what it doesn’t

The TGA says retatrutide is investigational and has not been approved by it or any comparable regulator. A product obtained outside a legitimate clinical trial may therefore be counterfeit. In this case, the regulator found a different active drug in the vial.

Semaglutide is associated with gastrointestinal effects including nausea and vomiting. In clinical trials, gastrointestinal events were common and tended to occur particularly during dose escalation; the STEP 1 semaglutide trial and a pooled analysis of STEP trials provide relevant context. That background does not establish what happened in this individual case beyond the regulator’s account.

The limits matter. This is one reported case. The public advisory does not state the exact semaglutide concentration or publish batch data. The causal chain linking the product to the oesophageal tear is the regulator’s characterisation, not a finding from an independent clinical trial. The report does not establish that all products sold as retatrutide are substituted, or that correctly prescribed semaglutide causes the same outcome.

What it does establish is narrower and important: the product tested was sold as one compound but contained another. A label is a claim, not evidence of contents.

The UK context: related risks, separate events

The Australian case is not a UK case. But the UK has its own evidence of risks in unregulated medicines supply.

In July 2026, the MHRA warned that retatrutide is not authorised for use in the UK. It cautioned that products sold under that name have not been tested for safety, quality or effectiveness, and may not contain retatrutide. In May, the MHRA reported seizing around 12,000 doses of unlicensed weight-loss medicines from a suspected manufacturing and distribution operation, including products believed to include retatrutide and tirzepatide. That seizure does not mean every product was chemically tested or confirmed as counterfeit.

The MHRA has also identified falsified Mounjaro (tirzepatide) 15 mg KwikPens in the UK supply chain. These examples are distinct from the TGA’s semaglutide-substitution finding, but together they underline why presentation and supplier claims cannot replace verification.

UK medicines supply is governed principally by the Human Medicines Regulations 2012 alongside relevant provisions of the Medicines Act 1968. The MHRA’s borderline-products guidance explains that a product’s status depends on factors including its claims, intended purpose, mode of action and presentation. Calling a product “research use only” does not make it suitable for human use or override medicines regulation. Retatrutide is not licensed in the UK and should not be used outside a legitimate clinical trial.

Why identity comes before purity

HPLC (high-performance liquid chromatography) separates components in a sample and can help assess relative purity. Mass spectrometry (MS) helps check whether the measured molecular mass is consistent with the declared compound. For peptide identity, the method and interpretation matter: mass alone may not distinguish all structurally similar molecules, so sequence confirmation or an appropriate complementary method may be needed for the question being asked.

The order of review should be clear:

1. Identity: Is the substance consistent with the compound declared?
2. Purity: How much of the measured sample corresponds to the identified compound?
3. Traceability: Does the evidence apply to the specific batch in the vial?

A sample can produce a clean, dominant HPLC peak and still be the wrong compound. A purity number without identity evidence can create false confidence.

Illustrative image only. It does not show an actual AXIOM batch report or test result.

A practical identity-verification checklist

Before accepting a research compound into a study, please check the following:

1. Compare the expected and observed molecular mass. Confirm that the COA’s MS data are consistent with the compound’s known mass. Check the measurement method and interpretation, including charge states or adducts where relevant. For sequence-sensitive work, ask what supports sequence identity.
2. Check the exact compound name. The COA should name the specific compound and identify the analytical sample. A generic “peptide blend” or vague category is not enough.
3. Match the batch to the vial. Require documentation for the lot in your hand. A report for an earlier batch, or a generic certificate with no matching batch number, cannot verify the current vial.
4. Review the HPLC chromatogram. Check whether the reported retention time is consistent with the declared compound under the stated method. Retention time is useful supporting evidence, not standalone proof of identity.
5. Look for transparent, batch-level testing. Prefer suppliers that publish third-party results openly and re-test each batch, with documentation traceable to the product you received.

QR batch codes can make it quicker to locate documentation, but a QR code is only useful if it leads to relevant, verifiable, batch-specific information. Our guide to batch ID and QR-code traceability explains what to look for. For a closer look at analytical paperwork, see our guide to reading a peptide COA and our overview of third-party tested peptides.

How AXIOM approaches documentation

At AXIOM Health, our stated quality approach centres on research-grade precision, batch documentation and clear analytical information. Our AX-Reta 10 mg product page describes the compound as for in-vitro research use only and provides product specifications. Please assess any batch using the actual batch-specific documentation available to you; a product page or label is not a substitute for examining the report for the vial in hand.

For our broader approach to disciplined, documented research, visit Life x Lab. You can also read our retatrutide research guide, which discusses the investigational compound’s research context. These resources are educational and do not imply that retatrutide is licensed or suitable for human use.

The takeaway for UK researchers

The TGA case is a reminder to verify what the compound is before focusing on how pure it appears. Identity data, batch-specific COAs, appropriately interpreted chromatograms and traceable third-party results are practical safeguards against substitution. None can turn an unlicensed product into a medicine approved for human use.

If you have used a product sold as retatrutide and develop severe or persistent symptoms, seek urgent medical advice and take the vial or packaging with you. The MHRA advises people not to use suspected falsified medicines and to report concerns through its Yellow Card scheme.

For research purposes only. Retatrutide is investigational, not licensed in the UK, and should not be used outside a legitimate clinical trial.